Your peptide “did nothing” — five reasons that aren’t the molecule

This is the written version of Your Peptides Aren’t Working. Here Are The 5 Reasons. — watch it instead if you’d rather.

There is a particular sentence I have heard on every plant I have ever worked on, usually delivered with total confidence by somebody holding a clipboard: “it doesn’t work.” It is a useful sentence, because it tells you a fault exists. It is a useless sentence, because it tells you nothing about where. My whole job as a chartered chemical process engineer is the gap between those two things — taking a process that should work, doesn’t, and finding out which of the boring, unglamorous links in the chain actually broke.

A peptide is just a very small, very expensive process. And “I felt nothing, so it doesn’t work” is that same clipboard sentence: a fault report being passed off as a diagnosis. Before the molecule takes the blame, five much more likely suspects have to be ruled out. In my experience it is almost never the molecule. It is almost always one of these.

One: you closed the trial before it opened

The most common failure by a wide margin, and the least interesting, which is exactly why nobody wants it to be the answer. People run something for ten days, look in the mirror, see the same person, and file a one-star review.

But a repair peptide is not a pre-workout. It is not designed to hit in twenty minutes and it has no mechanism by which it could. What compounds in that family are doing — where they do anything at all — is nudging slow biology: collagen laid down, new vessels built, tissue remodelled. That is work measured in weeks, not days. Realistically you are looking at four to six before you could fairly judge anything, and even then you are judging a subjective outcome with no control arm.

Ripping up the protocol on day ten is like binning a cake because it looked like soup two minutes into the oven. The recipe was not wrong. You opened the door too early.

Two: the arithmetic, not the molecule

Almost everybody in this space mixes their own vials. A dry powder, some bacteriostatic water, a syringe, and a number half-remembered from a forum post. Bathtub chemistry. And if that arithmetic is off by a factor you never noticed, what you are actually administering is mostly water.

This matters more than it sounds, because of something every pharmacologist takes for granted and almost no consumer does: there is a floor. Dose-response is not a straight line from zero. Below a certain threshold the biology simply shrugs — not a reduced effect, no effect. You can be one decimal place away from a real response and get a completely flat result, which reads to you as “this compound is a dud” rather than “I built the solution wrong.”

That is not the molecule failing. That is a rounding error on a syringe. I have written up the actual reconstitution maths — concentration, volume, and what happens to the vial afterwards — in the reconstitution and shelf-life piece, and it is worth ten minutes of anyone’s time before they conclude anything about efficacy.

Three: the awkward one

Some of what people feel — good and bad — is expectation. Nobody enjoys hearing that about a thing they paid for, so let me be precise about what is and is not being claimed.

Placebo responses are real, measurable, and strongest exactly where this field lives: subjective outcomes. Energy. Mood. Pain. Sleep quality. “I feel sharper.” These are the endpoints most likely to move on expectation alone, and they are also the endpoints almost every anecdote in a comment section is built from.

This is why those comment sections turn into a civil war. One person swears a compound changed their life; the next says it is snake oil; and the uncomfortable possibility is that both are accurately reporting their own experience. Neither of them ran a control. Neither of them was blinded. The fix is not more conviction — it is controlling the variables you actually can. Which brings us to the biggest variable nobody controls.

“It didn’t work” is a fault report. It is not a diagnosis, and it is not evidence about the molecule.

Four: what was actually in the vial

The uncomfortable structural fact about the gray market is that nothing in it is obliged to be what the sticker says. Independent testing and pharmacovigilance analyses keep turning up the same pattern in vials bought off the open internet: a real share come back under-dosed, impure, or simply not the compound named on the label. Chainalysis’ own look at the payment rails behind this trade gives you a sense of the scale of the thing — this is a large, fast, and structurally unaccountable supply chain.

And the certificate of analysis that gets waved around as proof? A PDF is trivially easy to produce. A COA is a claim about a batch, not a property of the vial in your fridge, and it is only as good as the laboratory and the chain of custody behind it — neither of which you can see.

So, congratulations: whether you wanted the job or not, you have become your supplier’s quality-control manager. That is not a rhetorical flourish, it is the actual position you are in, and I have set out what the role involves in why you are the QA department. If you want the narrower skill of reading one of these reports without a chemistry degree, that is here.

One honest caveat on the numbers that circulate about failure rates. The most-quoted commissioned testing in this space was paid for by a commercial peptide-review site that also runs a vendor directory. The samples went to a genuine independent analytical laboratory, but the work was commissioned by an interested party and was never peer-reviewed or independently published. Treat it as industry testing, not evidence — I will name the source type, but this channel does not point at vendor directories.

Five: it may have been finished before it reached you

Here is the one almost nobody checks, and the reason I saved it for last. Your compound may have died in transit.

These molecules are physically fragile in ways that are well documented in the formulation literature. Heat, light, and — crucially — repeated freeze-thaw cycles break them down and drive aggregation, and heat stress and freeze-thaw stress do their damage by different routes, which is why surviving one tells you nothing about the other. A peptide sitting in solution is a fundamentally less stable proposition than the same peptide as a dry solid; that is the entire reason it was shipped dry in the first place.

Now picture the actual journey. Synthesised overseas. Sat in a warehouse of unknown temperature. Flown across an ocean in a hold. Handed to a courier. Parked on a doorstep in the sun for eight hours while you were at work. Nothing in that chain is monitored, and nothing in it is logged.

And the vial that comes out the other end can look absolutely perfect. Clear liquid, cap intact, powder that reconstitutes cleanly. There is no warning light. Degradation of this kind is invisible to the eye, which is precisely what makes it the default explanation nobody reaches for. The “useless” compound was not lying to you. It just did not survive the trip.

The bottom line

Before you write anything off, run the five checks. Did you give it enough time to do slow work? Was the arithmetic right, and above the floor? Did you verify the source, rather than trust a PDF? Was it stored and shipped like the fragile thing it is? And have you separated the result from your own expectation of it?

Nine times out of ten, “it didn’t work” resolves to one of those five and not to the molecule. That cuts both ways, and I want to be honest about the second edge: ruling out five execution failures does not promote a compound to “effective.” Plenty of these things genuinely do not work, and I have graded them accordingly elsewhere. But you cannot learn anything from an experiment you ran badly — and right now, most people are running the experiment badly and drawing a confident conclusion from it anyway.

Fix the process first. Then judge the molecule. Keep safe, keep skeptical.

Sources

1. Angkawinitwong U, Sharma G, Khaw PT, Brocchini S, Williams GR, “Solid-state protein formulations”, Therapeutic Delivery, 2015;6(1):59–82 — why a dried peptide is a fundamentally different stability problem from one sitting in solution — https://doi.org/10.4155/tde.14.98
2. Cleland JL, Powell MF, Shire SJ, “The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation”, Critical Reviews in Therapeutic Drug Carrier Systems, 1993;10(4):307–77 — the degradation routes themselves — https://pubmed.ncbi.nlm.nih.gov/8124728/
3. Zhang A, Singh SK, Shirts MR, Kumar S, Fernandez EJ, “Distinct aggregation mechanisms of monoclonal antibody under thermal and freeze-thaw stresses revealed by hydrogen exchange”, Pharmaceutical Research, 2012;29(1):236–50 — heat stress and freeze-thaw stress damage a molecule by different routes — https://doi.org/10.1007/s11095-011-0538-y
4. Puig M & Shubow S, “Immunogenicity of therapeutic peptide products: bridging the gaps regarding the role of product-related risk factors”, Frontiers in Immunology, 2025 — why aggregates and impurities are treated as a product-quality risk factor, not a cosmetic one — https://doi.org/10.3389/fimmu.2025.1608401
5. “Gray-Market Peptides — Pharmacovigilance Safety Analysis”, Preventive Medicine Daily — independent findings that gray-market vials are frequently under-dosed, impure or mislabeled — https://www.preventivemedicinedaily.com/drug-safety/gray-market-peptides-safety-risks/
6. Chainalysis, “Inside the $100M Gray Market Peptide Crypto Boom”, 4 June 2026 — the scale and structure of the unregulated supply chain — https://www.chainalysis.com/blog/gray-market-peptide-crypto-boom/

Educational and research purposes only — not medical advice. Peptide Corner does not recommend any vendor, source, or dose. Keep safe, keep skeptical.